Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalpiciclib plus neoadjuvant endocrine therapy versus neoadjuvant chemotherapy in HR-strong-positive, HER2-negative breast cancer
ChiCTR2400080576Phase 2Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of dalpiciclib in breast cancer (2 arms), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Residual cancer burden 0-I rate. Started Feb 2024; status: recruiting.
02
Drugs
dalpiciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2400080576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400080576.